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1. Introduction 
During recent years, considerable effort has been made to develop proteomics technologies, 
with the aim of providing a complementary approach to the genomics tools already used in 
biomedical settings. This development has been extremely fast, and a number of emerging 
methodological proteomics tools now allow scientists to study the variable aspects of 
proteins in particular cell types, tissues or disease states. These tools include antibody 
arrays, two-dimensional-gel electrophoresis (2D-GE) and mass spectrometry (MS), the latter 
knowing an increasing use. In particular, candidate or non-candidate-based analyses of cell 
signalling represent powerful approaches for the investigation of the answers developed by 
cells in response to genetic modifications. Signalling molecules are key players in the 
regulation of the numerous and various biological processes occurring in a cell, and the 
alteration of signalling pathways has been associated with multiple diseases. Alterations in 
individual signalling pathways have been described in neuromuscular disorders, however, 
little information is available regarding their putative implication in Duchenne Muscular 
Dystrophy (DMD).  
DMD is an X-linked neuromuscular disorder that affects 1 newborn in 3500. This recessive 
disease represents the most common and severe form of muscular dystrophy. Although the 
genetic basis of the disease is well resolved, the cellular mechanisms associated with the 
physiopathology remain largely unknown. Increasing evidence suggests that mechanisms 
secondary to the dystrophin deficiency at the basis of the disease, such as alterations in key 
signalling pathways, may play an important role. Proteomic profiling of dystrophic vs 
healthy skeletal muscle can help to generate a DMD-specific proteomic signature. 
Understanding which particular signal transduction pathways are involved in muscular 
dystrophy might provide a basis for new target and therapeutic agents discovery. This 
chapter examines signalling pathways status in skeletal muscles from the Golden Retriever 
Muscular Dystrophy (GRMD) dog, the only clinically relevant animal model for DMD 
(Valentine et al., 1988; Cooper et al., 1988). More specifically, we will describe how 
proteomic studies were successfully used to identify reliable biomarkers of the disease in 
animal models. 
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2. Signalling pathways and DMD 
In dystrophic muscles, the absence of dystrophin, and the consequent destabilization of the 
dystrophin-glycoprotein associated complex DGC (a multiprotein transmembrane complex), 
lead to the loss of sarcolemma integrity, calcium overload, calpains activation and finally, 
necrosis of the myofibers (Muntoni et al., 2003). Besides providing mechanical stability, the 
DGC interacts with several proteins, including growth factor receptor-bound protein 2 
(Grb2) (Yang et al., 1995), neuronal nitric oxide synthase (nNOS) (Brenman et al., 1995), 
calmodulin (Madhavan et al., 1992), focal adhesion kinase (FAK) (Cavaldesi et al., 1999) and 
caveolin-3 (Crosbie et al., 1998), that play a role in cell signalling. Grb2 has been identified as 
a component of the Ras/ mitogen-activated protein kinases (MAPK) signalling pathway and 
both FAK and Grb2 function as mediators of survival signalling in various cell types, often 
working through the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway 
(Langenbach&Rando, 2002). Even if this mechanism can, in part, account for the 
degenerative phenotype observed in DMD, it seems increasingly obvious that the 
deregulation of intracellular signalling pathways also plays a role. These pathways, which 
are implicated in the regulation of crucial processes such as the balance between apoptosis 
and cell survival or the equilibrium between atrophy and hypertrophy, involve cascades of 
phosphorylation/dephosphorylation events. Protein kinases represent key enzymes 
responsible for the phosphorylation of specific targets. Moreover, altered cell signalling is 
thought to increase the susceptibility of muscle fibers to secondary triggers, such as 
functional ischemia and oxidative stress, and free-radical scavengers can have a direct 
impact on the activity/phosphorylation of some components of the MAPK cascades (Hnia et 
al., 2007). In progressive muscular dystrophy, muscles are characterized by hypertrophy in 
the early phase, while atrophic changes are observed with aging (Noguchi, 2005). 
Studies of the X chromosome-linked muscular dystrophy (mdx) mouse model of DMD 
(Bulfield et al., 1984) revealed modulations in MAPK signalling cascades, as dystrophic 
animals exhibited increased phosphorylation of extracellular signal-regulated kinases 1 and 
2 (ERK1/2) (Kumar et al., 2004; Lang et al., 2004) and c-jun N-terminal kinases 1 and 2 
(JNK1/2) (Kolodziejczyk et al., 2001; Nakamura et al., 2005; St-Pierre et al., 2004), and 
decreased phosphorylation of p38 (Lang et al., 2004). The PI3K/Akt signalling pathway has 
also been shown to be affected in the mdx mouse, with an increased synthesis and 
phosphorylation of Akt observed (Dogra et al., 2006; Peter&Crosbie, 2006). Studies finally 
demonstrated that directly modulating signalling pathways activity could improve mdx 
muscle function (Kim et al., 2010; Tang et al., 2010). More specifically, increasing Akt activity 
by transgenic overexpression of the activated kinase itself has been shown to be able to 
reverse the dystrophic phenotype (Blaauw et al., 2009; Peter et al., 2009). 
Moreover, the phosphorylation status of Akt was shown to be altered in human and canine 
dystrophic biopsies (Peter&Crosbie, 2006; Feron et al., 2009). Enhanced expression and activity 
of the phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (PTEN) has been observed in 
dystrophin-deficient dog muscle, and proposed to be at the origin of Akt inactivation (Feron et 
al., 2009). Indeed, PTEN opposes PI3K action by dephosphorylating phosphatidylinositol 
(3,4,5)-triphosphate (PtdIns(3,4,5)P3) (Maehama&Dixon, 1998) and the increased activity 
detected in GRMD muscle would presumably lead to a decreased level of the 
phosphoinositide, which should limit the recruitment and activation of Akt (see Figure 1 for a 
schematic representation of the signalling pathway deregulation in dystrophic dog muscle).  
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Fig. 1. Schematic diagram of signalling in the PI3K/Akt pathway and deregulations 
detected in GRMD skeletal muscle. Proteins shown in red, green and yellow indicate 
decreased, increased and unchanged level of expression or activity of these enzymes in 
GRMD vs. healthy muscle, respectively. As protein phosphatase 2A (PP2A) activity was not 
statistically modulated in GRMD muscle, the protein is shown in yellow. The deregulations 
detected in GRMD skeletal muscle could lead to decreased protein synthesis and block 
compensatory hypertrophy. 
Akt directly phosphorylates glycogen synthase kinase-3 (GSK3 at Ser9, thereby repressing 
its activity (Cross et al., 1995), and catalyses, via the mammalian target of rapamycin 
(mTOR), 70-kDa ribosomal protein S6 kinase (p70S6K) phosphorylation and activation 
(Chung et al., 1992; Glass, 2005; Inoki et al., 2002; Inoki et al., 2005; Price et al., 1992) (Figure 
1). The PI3K/Akt/GSK3 and PI3K/Akt/mTOR/p70S6K pathways have been implicated in 
the regulation of skeletal muscle mass. Akt/mTOR signals were found to be upregulated 
during hypertrophy and downregulated during atrophy and the activation of Akt or 
p70S6K (or inactivation of GSK3appeared to be sufficient to induce hypertrophy. 
Moreover, in addition to acting as an inductive cue for hypertrophy, activation of the 
Akt/mTOR pathway could also prevent muscle atrophy in vivo (Bodine et al., 2001; Rommel 
et al., 2001). Furthermore, it has been shown in vitro that the overexpression of Src homology 
2 (SH2) domain-containing inositol-5’-phosphatase 2 (SHIP-2), which, like PTEN, decreases 
PIP3 level, led to atrophy whereas the overexpression of a dominant negative mutant, which 
increases PIP3 level, induced hypertrophy (Rommel et al., 2001). The overexpression of 
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SHIP-2 in healthy mice muscle had no effect on fiber size but the overexpression of the 
phosphatase in a model of compensatory hypertrophy completely blocked the hypertrophy 
response (Bodine et al., 2001). It is thereby likely that the overexpression and increased activity 
of PTEN detected in GRMD muscle (by decreasing Akt activity and p70S6K phosphorylation, 
and by activating GSK3 could prevent compensatory muscle hypertrophy. More recently, 
the peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1) and 
PTEN inhibitor DJ-1/Parkinson disease (autosomal recessive early-onset) 7 (PARK7) appeared 
substantially reduced in GRMD vs healthy muscle (Feron et al., 2009; Guevel et al., 2011). 
Given the role of DJ-1 in the regulation of PTEN, this suggests that PTEN activation in GRMD 
dog muscle may originate from the under-expression of DJ-1. Noteworthy, in addition to its 
role in PTEN’s regulation, DJ-1 also promotes the activity of PGC-1 (Zhong&Xu, 2008). As 
such, DJ-1 sensitive signalling pathways may provide high priority targets for the 
development of novel drug therapies for DMD.  
Thus, compelling evidence suggest that alterations in signal transduction pathways may 
represent significant contributing factors to the progression of DMD. Proteomic profiling 
performed on the mdx mouse (Doran et al., 2006; Lewis et al., 2009; Ohlendieck, 2011) and 
GRMD dog models (Feron et al., 2009; Guevel et al., 2011) identified signalling proteins and 
reliable biomarkers of the secondary changes taking place in dystrophic muscles.  
3. Proteomic analysis of dystrophic dog muscle 
Proteomic approaches have been developed in order to try to identify putative biomarkers 
of DMD. The proteome-wide investigation of proteins requires technological efforts in three 
essential steps: the separation, the identification and the quantification of multiple proteins. 
Reversible protein phosphorylation is arguably the most common and significant 
mechanism for the dynamic control of biological processes. Phosphorylation can 
dramatically alter a protein’s biological location and/or activity and recent studies clearly 
highlighted the involvement of phosphoproteins and kinases in DMD (Kolodziejczyk et al., 
2001; Kumar et al., 2004; Lang et al., 2004; Peter&Crosbie, 2006; Feron et al., 2009). Although 
up to one-third of the total proteome might be phosphorylated, the absolute levels of any 
single protein specie might be very low. In contrast to the traditional biochemical study of 
single proteins or isolated pathways in the context of muscular dystrophy, technical 
advances in the high-throughput screening by MS and array-based technology have 
established new ways of identifying entire cellular proteins populations in one shift 
analytical approach. 
Global identification of signalling proteins can be done by a dedicated approach using 
antibody arrays. Antibody arrays also serve as an attractive option to carry out 
phosphoproteomic profiling in disease (Feron et al., 2009; Gembitsky et al., 2004; Kingsmore, 
2006). Phospho-specific antibody arrays commercially available facilitate the investigation of 
specific activated pathways in muscular disorders. On the other hand, a considerable 
number of proteomic studies have employed unbiased technology such as 2D-GE and stable 
isotope-labelling techniques combined with MS. To construct an accurate model of the 
proteome variations occurring in dystrophic dog muscle, complementary proteomic 
screenings have been done (Figure 2).  
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Fig. 2. Schematic diagram of the proteomic analysis of dystrophic dog muscle. H&E 
(hematoxylin and eosin) staining showing classical pathological changes of DMD, including 
fiber size variation, fiber splitting, and central nucleation in skeletal muscle. 2D-GE, isotope-
coded affinity tag (ICAT) quantitative proteomic analysis and antibody array of proteins 
purified from 4-month-old healthy and GRMD dog muscle. 
3.1 Protein array profiling 
Biomedical research of the 21st century will largely be based on the results of studies 
focusing on the evaluation of gene expression and performed in order to develop molecular 
tools for the diagnosis and treatment of human diseases. Currently, DNA arrays represent 
the most commonly used means to follow gene expression in health and disease, and in 
muscular dystrophies in particular (Chen et al., 2000; Rouger et al., 2002). However, gene 
expression studies are limited by several aspects: i) gene expression levels do not necessarily 
reflect the level of proteins (that can also be regulated by degradation), ii) the activity of 
some proteins is regulated by posttranslational modifications (PTM) such as phosphorylation, 
glycosylation, carbonylation, acetylation and ubiquitylation, or by allosteric modifications 
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and iii) localization changes can also play roles in this regulation. On the other hand, a lot of 
studies have been focusing on single proteins, protein complexes or isolated pathways, 
limiting the understanding of the pathogenesis of DMD at the organism level. In order to 
obtain this information and to be able to measure in parallel the expression and the state of 
activation of several hundreds of proteins, it was important to develop new approaches. 
Protein array-based approaches can provide not only data complementary to DNA 
microarrays but also provide unique information about the functional state of proteins 
under normal and pathological conditions (Hanash, 2003; MacBeath, 2002). Miniaturized 
protein array technology has opened a new chapter in biotechnology due to its ability to 
compare, characterize and quantify simultaneously a large number of proteins in the form 
of spots, thus replacing numerous individual protein by protein tests.It also allows parallel 
evaluation of several parameters in complex biological solutions. Moreover, a minute spot 
with immobilized protein sample on an array slide provides greater sensitivity for the 
detection of molecular interactions compared to other binding assays (Ekins&Chu, 1999). 
For the first time, antibody arrays were used by Anderson group to look for protein 
expression changes in spinal muscular atrophy (Anderson&Davison, 1999). A relatively 
small number of differences were found within a group of proteins that function as both 
RNA binding proteins and transcription factors. A second group used microarrays to profile 
the level of proteins associated with calcium regulation in sarcoplasmic reticulum isolated 
from muscle (Schulz et al., 2006). They used a reverse-phase protein array printed with 
proteins from genotyped animals and probed with seven target proteins important in 
calcium regulation. Reverse-phase arrays have been used for profiling phosphorylated 
proteins in various cancers (Grubb et al., 2003; Sheehan et al., 2005), and it was hoped that 
these arrays would become a powerful clinical tool for diagnosis and therapy guidance in 
different diseases.  
More recently, the antibody array technology was used to assess the phosphorylation status of 
key proteins of the MAPK and PI3K/Akt signalling pathways in the Vastus lateralis muscle 
from 4-month old GRMD vs healthy dogs. The antibody array technology represents a 
powerful tool for the semi-quantitative comparison of the expression and/or phosphorylation 
level of a high number of proteins in a limited number of samples (Sakanyan, 2005; Yeretssian 
et al., 2005). The main advantage resides in the gain of time that it provides, as a high number 
of proteins can be studied in just one experiment. Moreover (and in contrary to the ICAT 
technology for example), antibody arrays give access to information about PTM, such as 
phosphorylation, which is of course crucial in the context of cell signalling. Though it 
represents a biased technique (data is obtained only for the antibodies initially spotted on the 
membrane) but, as hundreds of different antibodies can be spotted onto the same membrane, 
it can easily be used for screening purposes such asfor disease diagnosis using disease 
biomarkers. This study indicated that Akt1, GSK3 and p70S6K, as well as ERK1/2 and the 
p38 and  kinases all displayed a decreased phosphorylation level in canine dytrophic muscle 
(Figure 3). Antibody arrays allow the detection of the presence of specific proteins, and the 
level of expression of phospho-proteins in disease tissue (Cahill, 2001), thus having a potential 
for biomedical and diagnostic applications. However, it had not been possible to address the 
systematic analysis of proteins using this dedicated approach.  
A lot of evidence now indicates that various signalling and metabolic pathways are altered 
in DMD, and a global, unbiased, proteomics study was necessary to identify these 
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perturbations. In order to characterize the complete dystrophic proteome, the use the recent 
2D-GE technology coupled to MS became favorable. 
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Fig. 3. Antibody array analysis revealed PI3K/Akt and MAPK signalling pathway 
modulation in GRMD skeletal muscle. Healthy and GRMD muscle extracts from 4-month-
old dogs were incubated with two antibody arrays. A ratio of signal intensity 
(GRMD/healthy) was calculated, and log transformed (base2). A cutoff value was 
determined by ANOVA analysis at 95% confidence level (p<0.05). * - significantly different 
from healthy muscle.  
3.2 Mass spectrometry-based proteomic analyses 
MS-based proteomics represents an unbiased approach allowing the comprehensive 
cataloging of the whole protein alterations associated with a specific disease. This chapter 
outlines the findings from recent applications of MS-based proteomics for studying alterations 
in dystrophic dog muscle, and examines novel strategies to establish DMD-specific 
biomarkers.  
3.2.1 Separation of muscle proteins by two-dimensional gel electrophoresis 
2D-GE represents a highly reproducible and discriminatory technique that allows the 
analysis of the accessible (meaning soluble and abundant) muscle proteins. The proteins that 
appear differentially expressed between the different samples analyzed are then identified 
by high-throughput MS (matrix-assisted laser desorption/ionization time-of-flight - 
MALDI-ToF or electrospary ionization - ESI). Proteomics dataset are finally interlinked with 
international web-based gel electrophoretic and protein sequence databanks for 
comparative analysis. Modern mass spectrometers produce and separate ions according to 
their mass-to-charge ratio (m/z) with an extraordinary resolving power. MS-based analysis 
of the skeletal muscle proteome has already been successfully used in the context of muscle 
development, fiber type specification, fast-to-slow transformation, muscle growth and 
aging, and in the context of denervation-induced fiber damage, atrophy, obesity, diabetes 
and muscular dystrophies (Ohlendieck, 2010). Detailed 2D maps of the major soluble muscle 
proteome, including proteins involved in actomyosin apparatus, regulation of contraction, 
ion homeostasis, signalling, cytosolic and mitochondrial metabolism and stress response, 
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have been established for various mammals (Doran et al., 2009a). The results obtained by 
this high-throughput technology should then be confirmed by more classical techniques 
such as western immunoblotting and immunohistochemistry. For example, the mdx mouse 
model was employed in recent proteomics profiling studies which revealed new disease 
markers in dystrophin-deficient fibres (Doran et al., 2004; Doran et al., 2006a, 2006b; Gardan-
Salmon et al., 2011). A differential in-gel analysis (DIGE) analysis of mdx vs normal 
diaphragm muscle revealed a drastic differential expression pattern of 35 proteins, with 21 
proteins being decreased (including the F-box only protein 11 - Fbxo11, adenylate kinase 1 – 
AK1, and the calcium-binding protein regucalcin) and 14 proteins being increased, 
including the small cardiovascular heat shock protein cvHSP and muscle proteins such as 
vimentin, desmin and myosin heavy chain (MHC) (Doran et al., 2006a).  
More recently, the GRMD dog model was used to profile changes in protein abundance 
associated with DMD using 2D-GE. To eliminate the structural and contractile proteins that 
are over-abundant in crude protein extracts prepared from skeletal muscle, and to enrich the 
samples in signalling proteins, the study restricted the analysis to the cytosolic and 
phospho-enriched proteins of the Vastus lateralis muscle removed from 4-month-old healthy 
and dystrophic dogs. Among the differentially expressed proteins , 8 were chosen, 
according to their high level of dysregulation, for further identification by MS. This led to 
the identification of skeletal muscle markers involved in the contractile function and 
mitochondrial proteins involved in energy metabolism (Guevel et al., 2011). Although 2D-
GE analysis represents an efficient technique to identify relative changes in protein 
expression, it is not well suited for studying low-abundant proteins, which are often 
important regulators of cell signalling. The high abundance of cytoskeletal, contractile and 
chaperone proteins identified in the phospho-enriched sample combined with dynamic 
range issues associated with the 2D-GE approach hampered studies on skeletal muscle 
analysis. Recently, Hojlund and colleague used 1D-GE and high-performance liquid 
chromatography (HPLC)-ESI-MS/MS to characterize the proteome of human skeletal 
muscle (Hojlund et al., 2008). The proteins identified in this study provide a representation 
of the major biological function of healthy human skeletal muscle. To elucidate changes in 
the proteome associated with DMD, and to overcome disadvantages of 2D-GE, peptide-
centric approach can be used, which allows quantitative comparison of two samples. 
Numerous stable isotope-labelling techniques have been employed in quantitative shotgun 
proteomics, including isobaric tag for relative and absolute quantification (iTRAQ); isotope-
coded affinity tag (ICAT); and stable isotope labelling by amino-acids in cell culture (SILAC) 
(Ohlendieck, 2011). In dystrophic skeletal muscle, the ICAT labelling approach has been 
used for the quantitative proteomic profiling of healthy and GRMD dog muscles.  
3.2.2 Quantitative proteomic analysis 
ICAT labelling followed by LC-MS/MS was used to analyze the quantitative variations of 
the proteome in both a cytoplasmic and a phospho-enriched fraction prepared from the 
Vastus lateralis muscle of 4-month old healthy and GRMD dogs (Guevel et al., 2011). A total 
of 84 proteins appeared significantly altered (61 proteins from the cytosolic fraction and 36 
proteins from the phospho-enriched fraction, with an overlap of 13 proteins). These proteins 
were classified into 7 major categories including: i) muscle development and contraction, ii) 
glycolytic metabolism, iii) oxidative metabolism, iv) calcium ion homeostasis, v) 
intracellular signalling, vi) regulation of apoptosis, and vii) other functions. Gene Ontology 
www.intechopen.com
 
Proteomic Analysis of Signalling Pathway Deregulation in Dystrophic Dog Muscle 
 
131 
(GO) annotation of the altered proteome led to several key findings which might reflect the 
ongoing muscle regeneration taking place in dystrophic muscle. Among the proteins altered 
in the intracellular signalling category in the dystrophic muscle, protein phosphatase 1 (PP1) 
and DJ-1 appear particularly interesting. PP1, which is present in skeletal muscle, is known 
to regulate both glycogen and fatty metabolism, while promoting the dephosphorylation of 
myosin The protein DJ-1 (also called PARK7) was recently described as a negative 
regulator of PTEN (Kim et al., 2005; Villa-Moruzzi et al., 1996). Interestingly, the under-
expressed proteins primarily composed of metabolic proteins, many of which have been 
shown to be regulated by PGC-1. Interestingly, among the several PGC-1 targets 
identified to be under-expressed in dystrophic dog muscle, 5 (namely 6-
phosphofructokinase, phosphoglucomutase-1, aconitase 2, cytochrome c1 and fatty acid 
binding protein 3) have already been identified in a different transcriptomic study as under-
expressing in DMD compared to healthy human biopsies (Pescatori et al., 2007). PGC-1 has 
been described as a potent regulator of mitochondrial biogenesis and oxidative metabolism 
in skeletal muscle (Wu et al., 1999; Lin et al., 2002). In addition, activation of the peroxysome 
proliferator-activated receptor (PPAR)/PGC-1 pathway has been shown, by preventing the 
bioenergetic deficit observed, to efficiently improve a mitochondrial myopathy phenotype 
(Wenz et al., 2008), suggesting that PGC-1 mediated improvement of dystrophic muscle 
may rely (in part) on the restoration of PGC-1 mitochondrial targets (Handschin et al., 
2007). Interestingly, a recent study has shown that pharmacologic activation of PPAR/ 
also leads to an upregulation in the expression of utrophin A, which was concurrent with a 
partial correction of the dystrophic phenotype (Miura et al., 2009). Taken together, these 
results provide compelling new evidence that defects in PTEN and PGC-1contribute to 
profound signalling pathway deregulation in the canine model of DMD as well as to the 
disease progression. In addition, they demonstrate that proteomics tools are of particular 
interest for the study of muscular disorders. Recently, the combination of proteomics, 
metabolomics and fluoximics has confirmed the existence in the mdx mouse of perturbations 
that reflect mitochondrial energetic alterations (Griffin&Des Rosiers, 2009). The broad aim of 
these studies has been two-fold, first the identification of co-founding factors that promote 
or limit the disease progression and second, the identification of new biomarkers that could 
be used to more accurately define the disease status. 
4. Reliable biomarkers of DMD, with a special focus on signalling proteins 
As previously mentioned, the absence of a single protein (dystrophin) in muscle has 
devastating consequences. Despites the tremendous efforts that have been made for more 
than 20 years in order to try to understand how this initial genetic defect could lead to the 
progressive and irreversible muscle wasting observed, the pathogenesis of DMD has not 
been fully characterized. Furthermore, no curative treatment is yet available and DMD 
patients are still dying during early adulthood. The identification, at the proteome level, of 
the alterations associated with DMD is important for at least five reasons. By providing a 
better understanding of the pathogenesis of DMD, they should i) improve diagnosis, ii) 
enable a better monitoring of disease progression, iii) lead to the proposal of new 
therapeutic targets (in the perspective of a pharmacological treatment – alone or in 
combination with a gene or cell therapy approach), iv) enable the fast and efficient 
evaluation of the benefits provided by the treatments currently under study (are they able to 
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reverse the secondary changes associated with the absence of dystrophin?) and v) in some 
cases, they could even enable the improvement of a given therapy. Ideally, serum 
biomarkers should be identified (Cacchiarelli et al., 2011) allowing an easy and non invasive 
analysis, but a muscle muscular biopsy could always be used if necessary. 
Skeletal muscle proteomics represents a new and powerful analytical tool for the swift 
separation and identification of new biomarkers and, in the recent years, several reviews 
written mainly by Doran, Ohlendieck and their colleagues focused on the proteomics 
analysis, by 2D-GE and high-throughput MS, of skeletal muscle during aging or disease 
(Lewis et al., 2009; Griffin&Des Rosiers, 2009; Doran et al., 2009a; Doran et al., 2007a, 2007b). 
Although being extremely powerful for the identification of new biomarkers, the proteomics 
analysis of skeletal muscle encounters some limitations. In the particular case of DMD, some 
complications are also due to the increase in endomysial fat and connective tissue, changes 
in the interstitial volume, infiltration by immune cells, residual blood components or drastic 
transformations in contractile fiber types. However, MS is so sensitive that it can 
differentiate these effects in heterogeneous cell mixtures. On the other hand, it is not always 
easy to distinguish between a DMD-specific biomarker and a biomarker that is more linked 
to muscle degeneration in general. The detailed analysis of the overlapping results obtained 
in the studies of DMD vs dysferlinopathies vs age-induced muscle wasting may help to 
distinguish between common and more specific biomarkers. In parallel to 2D-GE, we 
successfully used the antibody array technology to compare cell signalling in dystrophic vs 
healthy dog skeletal muscle (Feron et al., 2009). Finally, metabolomics and fluxomics 
(metabolic flux anlysis) studies have been successfully performed on skeletal muscle 
(Griffin&Des Rosiers, 2009).  
In 2003, Ge and colleagues published the results of a proteomic analysis, using 2D-GE/MS, 
of mdx hindlimb skeletal muscle (Ge et al., 2003). Among the 60 proteins identified as 
differentially expressed in dystrophic vs healthy muscle (40 in the cytosolic fraction and 20 
in the microsomal one), AK1 (cytosolic fraction) appeared to be of particular interest, 
because of its dramatic decrease (> four-fold) and because of its role, along with creatine 
kinase (CK), in the regulation of nucleotide ratios and energy metabolism. The expression 
and activity of AK1 was reduced in mdx muscle at different stages (one, three and six 
months), suggesting a direct link with the deficiency in dystrophin. Decreased AK1 activity 
in mdx muscle could contribute to the energetic defect, the decreased force and the increased 
fatigability exhibited. At the same time, the redistribution of energy flow through the 
alternative and compensatory CK phosphotransfer system could limit cellular energy 
failure. In DMD patients, lower ATP levels and impaired energy metabolism had been 
reported very early, and several studies suggest that defects in energy metabolism could 
contribute to DMD pathogenesis.  
Ge and colleagues, in 2004, also published a study in which they compared by 2D-GE the 
proteome of mdx vs control hindlimb muscles at different stages of the disease (Ge et al., 
2004). Among the 46 differentially expressed cytosolic proteins detected at three months (10 
down- and 36 up-regulated proteins), 24 could be identified by MS. These proteins belong to 
five different functional categories, and illustrate the increase in protein turnover caused by 
the cycles of degeneration/regeneration characteristic of mdx muscles. Concerning 
metabolism and energy production (i), the reduction in AK1 was confirmed and an increase 
in the expression level of the CK, ATP synthase, ATP succinyl-CoA synthetase and 
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pyrophosphatase enzymes was detected, highlighting the general mitochondrial 
dysfunction and metabolism crisis taking place in dystrophic muscles. Concerning the 
serine protease inhibitor family (ii), an up-regulation was detected for protease inhibitor 
member 1a and serine protease inhibitors 3, 6 and 1-5, suggesting a partial inhibition of 
proteolysis in mdx muscles. Concerning growth and differentiation (iii), an increase was 
detected in the expression level of PP1, cofilin 2 (CFL2) and  14-3-3, indicating active 
proliferation and differentiation. Of interest, an increase in CFL2 had also been observed in 
human DMD biopsies. As far as calcium homeostasis is concerned (iv), the up-regulation of 
PP1 can also be cited, as the phosphatase binds to the ryanodine-sensitive calcium release 
channel protein to regulate calcium flux. The calcium-binding protein annexin V was also 
increased. Finally, and concerning cytoskeleton reorganization and biogenesis (v), RhoGDI-
1, -actin and tropomyosin 1 were found to be up-regulated in mdx muscles, indicating 
cytoskeleton remodeling. At one and six months, 62 and 48 differentially expressed proteins 
were detected, respectively. At one month, most of the proteins detected were down-
regulated whereas at six months (as it was the case at three months), most of them were up-
regulated. These results confirmed the specificity of the one month stage (“DMD-like” crisis) 
in the evolution of the disease in the mdx mouse. Six proteins were detected as differentially 
expressed in mdx vs healthy muscles at the three stages tested: AK1 (down-regulated), CK 
(up-regulated), myosin light chain 2 (MLC2, up-regulated), annexin V, tropomyosin and  
14-3-3 (all down-regulated at one month and up-regulated at three and six months). Some of 
these changes thus appear directly linked to the absence of dystrophin whereas some others 
appear more dependent of the phenotype on the muscle. The elevation detected in MLC2 
levels could reflect the proliferation/differentiation processes occurring in mdx muscles, as 
the protein is involved in muscle differentiation, and its consistent elevation during the 
progression of the disease suggests that mdx muscles may assume a chronic or abnormal 
differentiation state.  
In another study, Doran and colleagues performed a 2D-GE/MS-based subproteomics 
analysis of calcium-binding proteins by using the cationic carbocyanine dye ‘Stains-All’ 
(Doran et al., 2004). Among the 8 dye-positive proteins identified as greatly reduced in mdx 
vs healthy skeletal muscle, calsequestrin was present. Calsequestrin represents the main 
luminal sarcoplasmic reticulum calcium reservoir protein. It is a terminal cisternae 
constituent with high-capacity and medium-affinity, and acts as a mediator of the excitation-
contraction-relaxation cycle, both as a luminal ion trap and an endogenous regulator of the 
ryanodine receptor. The authors could also confirm the reduction in sarcalumenin, a 
calcium-shuttle element of the longitudinal tubules. These results of course confirm the 
calcium hypothesis of DMD. The reduction in calsequestrin could explain the impaired 
calcium buffering capacity of dystrophic sarcoplasmic reticulum, which is known to cause 
an increase in free cytosolic calcium level and thus in proteolysis. Previous microsomal 
study had not detected any change in the expression level of calsequestrin, highlighting the 
power of the technique used here.  
More recently, Doran and colleagues could also show, using 2D-GE/MS again, that another 
protein involved in calcium homeostasis, regucalcin, was reduced in young and aged mdx vs 
healthy diaphragm, limb and heart muscles (Doran et al., 2006a). Regucalcin represented the 
most interesting hit in respect to the calcium hypothesis of DMD as its reduced level could 
render mdx fibers more susceptible to necrosis. Regucalcin is a cytosolic calcium-handling 
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protein involved in signalling. By enhancing the calcium-pumping activity in the plasma 
membrane, endoplasmic reticulum and mitochondria, regucalcin appears as an important 
regulator that maintains low cytosolic calcium levels. Its reduced expression level could be 
confirmed by immunoblotting in the diaphragm muscle from 3-week-, 9-week-, 11-month- 
and 20-month-old mdx mice. At 9 weeks, a reduced level of the protein could also be 
observed in hindlimb and heart muscles. Doran and colleagues finally used the powerful 
DIGE technique and identified 2398 proteins among which 35 exhibited a differential 
expression level in mdx vs healthy diaphragm muscle (Doran et al., 2006b). These proteins 
are involved in muscle contraction, cytoskeleton formation, mitochondrial function, 
metabolism, ion homeostasis and chaperone function. The most interesting finding 
concerned the dramatic increase in the expression level of the small heat shock protein 
cvHSP (highest fold change). This drastic increase could be observed in 9-week- and 11-
month-old mdx diaphragm muscles (it increases with the age – in correlation with the 
severity of the phenotype). Whereas the protein was concentrated in subsarcolemmal 
regions in healthy muscle, it was shown to be present throughout the cytoplasm of mdx 
fibers, with a typical striated appearance suggesting an association with contractile elements 
and/or cytoskeletal components and a role in the stress response developed by mdx 
damaged fibers. This increase in cvHSP was associated with the differential expression of 
others key heat shock proteins (HSP20, GRP75, HSP90 and HSP110), emphasizing stress 
response as an important mechanism in DMD pathogenesis, and suggesting that it could be 
targeted by new pharmacological treatments. Heat shock chaperon proteins can be 
activated, besides by heat shock per se, by other stress factors such as inflammation, 
ischemia, oxidative stress, exposure to heavy metals or certain amino acids analogs. They 
prevent the aggregation of misfolded proteins as well as they influence the transport of 
mature proteins. The up-regulation of cvHSP observed in mdx diaphragm indicates an 
attempt of damaged muscle fibers to repair their cytoskeletal network. The change observed 
in the localization of the protein also suggests a protective role in muscle fiber degeneration. 
The up-regulation of chaperones probably represents an autoprotective mechanism, 
whereby the stress response can be considered as a reaction to the pathological increase in 
abnormally folded muscle proteins.  
More recently, a magnetic bead fractionation and MS-based serum protein profiling was 
performed in the mdx mouse and described coagulation Factor XIIIa, previously identified 
in human serum, as a potential biomarker of muscular dystrophy (Alagaratnam et al., 2008). 
Factor XIIIa plays roles in coagulation and cardiovascular biology, possibly through 
macrophage activation, and macrophages are known to infiltrate dystrophic muscles. 
Because blood serum analysis is fast, economical and non invasive, this type of study is of 
high interest, and a study with serum from DMD patients should be performed. However, 
this factor alone may not be sufficient to distinguish between DMD and other inflammatory 
context.  
Finally, our lab identified two signalling molecules (PTEN and PGC1-as biomarkers in 
GRMD dog model, strongly reinforcing the hypothesis that signalling pathways alteration 
could play a role in DMD pathogenesis. In a first study (Feron et al., 2009), we were able to 
show that an increase in the activity of PTEN, a phosphatase that counteracts Akt activation 
by dephosphorylating the PIP3 generated by PI3K (Maehama&Dixon, 1998), in dystrophin-
deficient dog muscle leads to a profound and long-term deregulation of the PI3K/Akt 
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signalling pathway. All the GSK3+ fibers observed in dystrophic muscle appeared to 
exhibite a strong accumulation of PTEN, whereas the fibers with weak PTEN labelling were 
systematically GSK3-. In order to see if the alterations initially detected at 4-months were 
specific of this age, the double labelling experiment was repeated at 3 months (when the 
morphological features of muscular dystrophy are yet very few) and 36 months (which 
corresponds to a very advanced stage). PTEN+/GSK3+ fibers could be observed at all 
stages, and we demonstrated that the alteration of the pathway could not be attributed only 
to a feature or regeneration or to a consequence of inflammatory changes. In conclusion, 
increased PTEN activity revealed to be a signature of muscular dystrophy pathogenesis in 
dog, leading to long-term and deep PI3K/Akt signalling pathway alteration. This 
dysregulation probably limits compensatory hypertrophy, thus exacerbating muscle 
degeneration, and these results could open the door to new potential therapeutic targets for 
the treatment of DMD.  
In a second analysis, a quantitative proteomic analysis of dystrophic vs healthy dog muscle 
was performed using the ICAT technology coupled to LC/MS/MS (Guevel et al., 2011). This 
study, performed on both a cytoplasmic and a phospho-enriched fractions, identified 84 
proteins as being differentially represented in GRMD vs healthy dog muscle. Interestingly, 
many of the under-expressed proteins detected have been previously shown to be regulated 
by PGC-1, and we were able to show that PGC1-expression was indeed dramatically 
reduced in GRMD vs healthy muscle. These results confirmed that defective energy 
metabolism is a central hallmark of the disease in the canine model, and reinforced once 
more the hypothesis that secondary changes may play an active role in DMD pathogenesis.  
In conclusion, proteomics studies performed in the recent years on dystrophic vs healthy 
muscles led to the identification of new biomarkers of DMD, such as AK1 (nucleotide 
metabolism), calsequestrin, regucalcin (calcium homeostais) and cvHSP (cellular stress 
response) in the mdx mouse and PTEN and PGC-1 (cell signalling: atrophy/hypertrophy and 
energy metabolism) in the GRMD dog. Other putative biomarkers were also identified in the 
following processes: nucleotide metabolism (CK, Atp5b), calcium homeostasis (sarcalumenin), 
cellular stress response (BC, chaperonins), muscle contraction (MHC and MLC, troponin, 
actin), intermediate filament formation (vimentin, desmin), glycolysis (glyceraldehyde-3-
phosphate dehydrogenase, aldolase), polyol pathway of glucose metabolism (sorbitol 
dehydrogenase), citric acid cycle (isocitrate dehydrogenase), fatty acid oxidation (electron 
transferring flavoprotein), aldehyde metabolism (aldehyde reductase, aldehyde 
dehydrogenase), formation of acetyl-coenzyme A (dihydrolipoamide dehydrogenase), 
remethylation pathway of homocysteine homeostasis (betaine-homocysteine 
methyltransferase), acid-base balance (carbonic anhydrase), oxygen transport (-haemoglobin, 
-globin), protein ubiquitination (Fbxo11) and transcriptional control (Jmjd1a). Taken together, 
these results indicate a drastic reduction in key metabolic regulators and a compensatory up-
regulation of structural elements. 
5. Proteomic profiling of experimental therapy  
As previously mentioned, no curative treatment is yet available for DMD patients that can 
benefit only from palliative care and generally die during early adulthood. Two therapeutic 
strategies can be envisaged to treat, or at least to alleviate the symptoms of DMD: try to 
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restore dystrophin expression in dystrophic muscle fibers (through gene or cell therapy 
approaches), or target the molecular pathways lying downstream of dystrophin (through 
pharmacological treatments). Several strategies have been recently set up in order to rescue 
dystrophin synthesis in animal models of DMD and some of them have now entered clinical 
trials (Kinali et al., 2009; van Deutekom et al., 2007). One of the major problems in 
comparing the benefit of different therapeutic treatments is to find common outcome 
measurements. This paragraph does not aim at describing in details the therapies currently 
under study [for a review, please see (Sugita&Takeda, 2010; Guglieri&Bushby, 2010; Zhang 
et al., 2007)], but rather to show how proteomic profiling could be used to evaluate the 
efficiency of therapeutic treatments. Recently, Doran and colleagues (Doran et al., 2009b) 
used DIGE analysis to evaluate the efficiency of an exon skipping-based strategy in the mdx 
mouse.  
The idea behind the study is that, as secondary mechanisms such as abnormal signalling, 
energy metabolism defects, alterations in ion homeostasis or in excitation-contraction 
coupling, probably play a crucial role in DMD pathogenesis, any novel therapeutic strategy 
should be evaluated on several aspects: re-expression of dystrophin (except for therapeutic 
treatments targeting downstream events), muscle function tests, but also correction of the 
secondary changes previously detected in the above mentioned processes.  
Proteomic profiling of exon skipping-treated mdx muscles showed that the re-expression of 
dystrophin led to the correction of the previously detected alterations in calcium handling, 
nucleotide metabolism, bioenergetic pathways, acid-base balance and cellular stress response. 
More precisely, the re-expression of dystrophin was associated with the restoration of -
dystroglycan and nNOS (two proteins associated with the DGC at the sarcolemma), and with 
a normal expression level of some biomarkers previously identified (namely calsequestrin, 
adenylate kinase, aldolase, mitochondrial creatine kinase and cvHsp). 
Both the primary and secondary abnormalities provoked by the absence of dystrophin were 
reversed, reinforcing the interest of the exon skipping strategy for the treatment of DMD. 
This study reinforced the role ofsecondary mechanisms in DMD pathogenesis, and it 
demonstrated for the first time the utility of evaluation of the effect of any novel therapeutic 
approach on both the re-expression of dystrophin and the indirect alterations associated 
with its absence. AK1, that had previously been reported as down-regulated in mdx 
diaphragm muscle (Ge et al., 2003), was restored after the antisense-induced exon skipping. 
Also, the down-regulation of the mitochondrial isozyme of CK was partially reversed. 
Accordingly, the known down-regulation of two others metabolic enzymes, namely aldolase 
and isocitrate dehydrogenase (Doran et al., 2006b) was also partially reversed. Conversely, 
the major increase previously reported in the level of cvHSP in mdx diaphragm was 
significantly reduced after treatment. As far as the acid-base balance is concerned, the 
expression level of carbonic anhydrase was also restored after treatment. For calsequestrin, 
an immunoblotting experiment (as DIGE is not well suited for the analysis of membrane 
proteins) was performed that revealed that exon skipping treatment was again able to 
restore its expression (Doran et al., 2004), suggesting a partial abolishment of the secondary 
changes in calcium homeostasis associated with DMD. The exon skipping strategy 
presented here effectively reverses both the metabolic crisis and the compensatory up-
regulation of different chaperones and enzymes associated with muscular dystrophy in the 
mouse.  
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Lastly, miRNAs specifically expressed in muscle cells and known to be released in the blood 
of DMD patients in a way proportional to the extent of muscle degeneration, could be used 
as biomarkers in the evaluation of therapeutic strategies (Cacchiarelli et al., 2011).  
To sum up, even though many different DMD therapeutic approaches are now entering 
clinical trials, a unifying method for assessing the benefit of different treatments is still 
lacking.  
6. Conclusion 
In conclusion, proteomics analysis plays a significant role in our ability to understand 
molecular mechanisms associated with DMD. Various technological platforms are now 
available for proteomic studies enabling us to address different aspects of dystrophic muscle 
governed by signalling pathways. We foresee proteomics emerging as a vital technique in 
clinical research to assist us in understanding which particular signal transduction 
pathways are involved in muscular dystrophy and to evaluate the benefit of clinical trials. 
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